Company: IOBT
Filing Date: 2025-11-21
Form Type: 8-K
Source: 0001193125-25-291504
Chunk: 0

Company: IO Biotech, Inc.
Filing Date: 2025-11-21
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

Resignation of Principal Accounting Officer

On November 17, 2025, Brian Burkavage informed IO Biotech, Inc. (the “ Company”) of his intent to resign from his position as the Company’s Senior Vice President and Chief Accounting Officer, effective December 12, 2025. Mr. Burkavage plans to pursue another opportunity, and his resignation is not the result of any dispute or disagreement with the Company.

Appointment of Principal Accounting Officer

Amy Sullivan, the Company’s Chief Financial Officer, has been designated as the Company’s principal accounting officer, effective upon Mr. Burkavage’ departure. Ms. Sullivan’s biographical information is contained under the heading “ Executive Officers” in the Company’s 2025 definitive proxy statement on Schedule 14A, which was filed with the U. S. Securities and Exchange Commission on April 25, 2025. No new compensatory arrangements will be entered into with Ms. Sullivan in connection with her service as principal accounting officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               IO BIOTECH, INC.                                   
  Date: November 21, 2025      By:                   /s/ Mai-Britt Zocca, Ph. D.  
                               Name:                 Mai-Britt Zocca, Ph. D.      
                               Title:                Chief Executive Officer